Ultragenyx Pharmaceutical Inc Reports Q3 2026 Revenue of $173 Million, Misses Estimates; Net ...
Total revenue of $173 million fell short of the $183.12 million analyst estimate, while the net loss per share of $1.16 trailed the estimated -$1.12 Related Stocks: RARE ,